ArticlePharmacological reports : PR2022
Real-world experience with molnupiravir during the period of SARS-CoV-2 Omicron variant dominance.
Robert Flisiak et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
25 papers cite it
this paperpooled itcites it